BeyondSpring (NASDAQ:BYSI – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.52, FiscalAI reports.
BeyondSpring Stock Down 15.8%
BeyondSpring stock traded down $0.16 during mid-day trading on Friday, hitting $0.84. 777,182 shares of the company’s stock traded hands, compared to its average volume of 282,435. BeyondSpring has a one year low of $0.73 and a one year high of $2.44. The firm has a 50 day moving average price of $1.39 and a 200 day moving average price of $1.50. The company has a market cap of $34.50 million, a PE ratio of -5.99 and a beta of 0.48.
Institutional Inflows and Outflows
A hedge fund recently raised its position in BeyondSpring stock. Geode Capital Management LLC lifted its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 16.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 368,682 shares of the company’s stock after purchasing an additional 53,198 shares during the quarter. Geode Capital Management LLC owned about 0.91% of BeyondSpring worth $601,000 at the end of the most recent reporting period. 40.29% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Read Our Latest Stock Analysis on BeyondSpring
BeyondSpring Company Profile
BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.
See Also
- Five stocks we like better than BeyondSpring
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
